Gianello (PubMed) Research Focus : Mechanistic Preclinical Research Title : Development of a Human Growth Hormone Peptide Analogue AOD9604 into an Anti-Obesity Drug (Book chapter, Peptides: The Wave of the Future, APSY vol 7, 2001) Authors : Woei-Jia Jiang, Robert Gianello, Mark Heffernan, Esra Ogru, Roksan Libinaki, Frank Ng (SpringerLink) Research Focus : Preclinical Lipid Metabolism Studies (Mice) Title : The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and -AR knockout mice (Endocrinology, Dec 2001) Authors : M
Conflict of interest Flynn McGuire, Riley Martinez, Annika Lenz, Lee Skinner, and Dan Cushman declare that they have no conflict of interest
Regular NAD+ therapy promotes healthier, more radiant skin as part of its overall impact on cellular health
pylori-related mucosal injury: Oral administration preferred capsules or solution, taken on an empty stomach Typical range: 250500 mcg/day in divided doses Cycle length: 46 weeks , may extend to 812 weeks for chronic conditions Some practitioners use SubQ in parallel for systemic anti-inflammatory support Potential Problems and Contraindications BPC-157 has a favorable safety profile in animal studies remarkably, no lethal dose (LD50) has been established in rodents even at extremely high doses